Generic placeholder image

Current Nanoscience

Editor-in-Chief

ISSN (Print): 1573-4137
ISSN (Online): 1875-6786

Review Article

Targeted Delivery Modalities in Combination with Biofunctionalized Metallic Nanoparticles (MNPs): Combating Amyloid Plaques

Author(s): Nishabh Kushwaha, Drishti Panjwani, Kshitija Akarte, Shruti Patel, Priyanka Ahlawat, Rajesh Kesarla, Mange Ram Yadav and Asha Patel*

Volume 22, Issue 1, 2026

Published on: 08 May, 2025

Page: [71 - 87] Pages: 17

DOI: 10.2174/0115734137361817250325071654

Price: $65

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by loss of memory and cognitive impairment. The pathogenesis of AD is complex and involves a variety of processes, including receptor-ligand interaction and receptor-mediated endocytosis. Biofunctionalized metallic nanoparticles (MNPs) represent a cutting-edge technique that addresses significant limitations of existing therapies by precisely delivering therapeutic molecules to disease-specific locations. The review explores innovative therapeutic strategies for Alzheimer's disease (AD), focusing on the roles of amyloid precursor protein and metal nanoparticles. It discusses drug delivery systems, including functionalized metallic nanoparticles, highlighting their potential in enhancing drug efficacy and targeting amyloid plaques. These biofunctionalized MNPs not only help pass the blood-brain barrier (BBB), but also lessen off-target effects and increase medication absorption. Furthermore, they facilitate emerging treatments, such as monoclonal antibodies, aptamers, CRISPR/Cas9 gene therapy, and proteolysis-targeting chimeras (PROTACs), showcasing their mechanisms and benefits in mitigating AD pathology. This paper focuses on MNPs’ ability to control neuroinflammation, a hallmark of AD pathogenesis, and their novel function in improving therapy results. By integrating current findings and addressing limitations in clinical translation, this review sheds light on the future of MNPs-assisted AD treatment.

Keywords: Metallic NPs, aptamers, amyloid plaques, antibody fragments, Alzheimer’s disease, blood-brain barrier.

Graphical Abstract
[1]
Bamford, R.A.; Widagdo, J.; Takamura, N.; Eve, M.; Anggono, V.; Oguro-Ando, A. The interaction between contactin and amyloid precursor protein and its role in Alzheimer’s disease. Neuroscience, 2020, 424, 184-202.
[http://dx.doi.org/10.1016/j.neuroscience.2019.10.006] [PMID: 31705890]
[2]
Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med., 2016, 8(6), 595-608.
[http://dx.doi.org/10.15252/emmm.201606210] [PMID: 27025652]
[3]
Spillantini, M.G.; Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol., 2013, 12(6), 609-622.
[http://dx.doi.org/10.1016/S1474-4422(13)70090-5] [PMID: 23684085]
[4]
Sharma, B.; Pervushin, K. Magnetic nanoparticles as in vivo tracers for Alzheimer’s disease. Magnetochemistry, 2020, 6(1), 13.
[http://dx.doi.org/10.3390/magnetochemistry6010013]
[5]
Ling, D.; Hyeon, T. Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small, 2013, 9(9-10), 1450-1466.
[http://dx.doi.org/10.1002/smll.201202111] [PMID: 23233377]
[6]
Chaparro, C.I.P.; Loureiro, L.R.; Valente, M.A.; Videira, P.A.; Borges, J.P.; Soares, P.I.P. Application of hyperthermia for cancer treatment: Synthesis and characterization of magnetic nanoparticles and their internalization on tumor cell lines. 2019 IEEE 6th Portuguese Meeting on Bioengineering (ENBENG), Lisbon, Portugal. 22-23 Feb 2019, pp. 1-4.
[http://dx.doi.org/10.1109/ENBENG.2019.8692485]
[7]
Soares, P.I.P.; Laia, C.A.T.; Carvalho, A.; Pereira, L.C.J.; Coutinho, J.T.; Ferreira, I.M.M.; Novo, C.M.M.; Borges, J.P. Iron oxide nanoparticles stabilized with a bilayer of oleic acid for magnetic hyperthermia and MRI applications. Appl. Surf. Sci., 2016, 383, 240-247.
[http://dx.doi.org/10.1016/j.apsusc.2016.04.181]
[8]
Soares, P.I.P.; Romão, J.; Matos, R.; Silva, J.C.; Borges, J.P. Design and engineering of magneto-responsive devices for cancer theranostics: Nano to macro perspective. Prog. Mater. Sci., 2021, 116, 100742.
[http://dx.doi.org/10.1016/j.pmatsci.2020.100742]
[9]
Diez-Pascual, A.M.; Rahdar, A. Functional nanomaterials in biomedicine: Current uses and potential applications. ChemMedChem, 2022, 17(16), e202200142.
[http://dx.doi.org/10.1002/cmdc.202200142] [PMID: 35729066]
[10]
Fu, Z.; Xiang, J. Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. Int. J. Mol. Sci., 2020, 21(23), 9123.
[http://dx.doi.org/10.3390/ijms21239123] [PMID: 33266216]
[11]
Zhang, R.; Qin, X.; Kong, F.; Chen, P.; Pan, G. Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv., 2019, 26(1), 328-342.
[http://dx.doi.org/10.1080/10717544.2019.1582730] [PMID: 30905189]
[12]
Santhosh, P.B.; Ulrih, N.P. Multifunctional superparamagnetic iron oxide nanoparticles: Promising tools in cancer theranostics. Cancer Lett., 2013, 336(1), 8-17.
[http://dx.doi.org/10.1016/j.canlet.2013.04.032] [PMID: 23664890]
[13]
Mittal, A.; Roy, I.; Gandhi, S. Magnetic nanoparticles: An overview for biomedical applications. Magnetochemistry, 2022, 8(9), 107.
[http://dx.doi.org/10.3390/magnetochemistry8090107]
[14]
Xu, J.; Sun, J.; Wang, Y.; Sheng, J.; Wang, F.; Sun, M. Application of iron magnetic nanoparticles in protein immobilization. Molecules, 2014, 19(8), 11465-11486.
[http://dx.doi.org/10.3390/molecules190811465] [PMID: 25093986]
[15]
Wang, J.; Wang, K.; Zhu, Z.; He, Y.; Zhang, C.; Guo, Z.; Wang, X. Inhibition of metal-induced amyloid β-peptide aggregation by a blood–brain barrier permeable silica–cyclen nanochelator. RSC Advances, 2019, 9(25), 14126-14131.
[http://dx.doi.org/10.1039/C9RA02358E] [PMID: 35519314]
[16]
Ruff, J.; Hüwel, S.; Kogan, M.J.; Simon, U.; Galla, H.J. The effects of gold nanoparticles functionalized with ß -amyloid specific peptides on an in vitro model of blood–brain barrier. Nanomedicine, 2017, 13(5), 1645-1652.
[http://dx.doi.org/10.1016/j.nano.2017.02.013] [PMID: 28285163]
[17]
Qin, J.; Guan, Y.; Li, Z.; Guo, X.; Zhang, M.; Wang, D.; Tang, J. Aptamer conjugated polydopamine-coated gold nanoparticles as a dual-action nanoplatform targeting β-amyloid peptide for Alzheimer’s disease therapy. J. Mater. Chem. B Mater. Biol. Med., 2022, 10(41), 8525-8534.
[http://dx.doi.org/10.1039/D2TB01499H] [PMID: 36222089]
[18]
Perneczky, R.; Jessen, F.; Grimmer, T.; Levin, J.; Flöel, A.; Peters, O.; Froelich, L. Anti-amyloid antibody therapies in Alzheimer’s disease. Brain, 2023, 146(3), 842-849.
[http://dx.doi.org/10.1093/brain/awad005] [PMID: 36655336]
[19]
Cummings, J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease therapeutics. Drugs, 2023, 83(7), 569-576.
[http://dx.doi.org/10.1007/s40265-023-01858-9] [PMID: 37060386]
[20]
Biogen. A phase 3 multicenter, randomized, double-blind, placebocontrolled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. Report No. NCT02484547, 2021.
[21]
Knopman, D.S.; Hershey, L. Implications of the approval of Lecanemab for Alzheimer disease patient care. Neurol., 2023, 101(14), 610-620.
[http://dx.doi.org/10.1212/WNL.0000000000207438]
[22]
Mintun, M.A.; Lo, A.C.; Duggan Evans, C.; Wessels, A.M.; Ardayfio, P.A.; Andersen, S.W.; Shcherbinin, S.; Sparks, J.; Sims, J.R.; Brys, M.; Apostolova, L.G.; Salloway, S.P.; Skovronsky, D.M. Donanemab in early Alzheimer’s disease. N. Engl. J. Med., 2021, 384(18), 1691-1704.
[http://dx.doi.org/10.1056/NEJMoa2100708] [PMID: 33720637]
[23]
Eli Lilly and Company In: Lilly-News Release. Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease; , 2023. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional
[24]
van Dyck, C.H. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: Pitfalls and promise. Biol. Psychiatry, 2018, 83(4), 311-319.
[http://dx.doi.org/10.1016/j.biopsych.2017.08.010] [PMID: 28967385]
[25]
McDade, E.; Cummings, J.L.; Dhadda, S.; Swanson, C.J.; Reyderman, L.; Kanekiyo, M.; Koyama, A.; Irizarry, M.; Kramer, L.D.; Bateman, R.J. Lecanemab in patients with early Alzheimer’s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res. Ther., 2022, 14(1), 191.
[http://dx.doi.org/10.1186/s13195-022-01124-2] [PMID: 36544184]
[26]
Cummings, J.; Osse, A.M.L.; Cammann, D.; Powell, J.; Chen, J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs, 2024, 38(1), 5-22.
[http://dx.doi.org/10.1007/s40259-023-00633-2] [PMID: 37955845]
[27]
van Dyck, C.H.; Swanson, C.J.; Aisen, P.; Bateman, R.J.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L.D.; Iwatsubo, T. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med., 2023, 388(1), 9-21.
[http://dx.doi.org/10.1056/NEJMoa2212948] [PMID: 36449413]
[28]
Sims, J.R.; Zimmer, J.A.; Evans, C.D.; Lu, M.; Ardayfio, P.; Sparks, J.; Wessels, A.M.; Shcherbinin, S.; Wang, H.; Monkul Nery, E.S.; Collins, E.C.; Solomon, P.; Salloway, S.; Apostolova, L.G.; Hansson, O.; Ritchie, C.; Brooks, D.A.; Mintun, M.; Skovronsky, D.M.; Abreu, R.; Agarwal, P.; Aggarwal, P.; Agronin, M.; Allen, A.; Altamirano, D.; Alva, G.; Andersen, J.; Anderson, A.; Anderson, D.; Arnold, J.; Asada, T.; Aso, Y.; Atit, V.; Ayala, R.; Badruddoja, M.; Badzio-jagiello, H.; Bajacek, M.; Barton, D.; Bear, D.; Benjamin, S.; Bergeron, R.; Bhatia, P.; Black, S.; Block, A.; Bolouri, M.; Bond, W.; Bouthillier, J.; Brangman, S.; Brew, B.; Brisbin, S.; Brisken, T.; Brodtmann, A.; Brody, M.; Brosch, J.; Brown, C.; Brownstone, P.; Bukowczan, S.; Burns, J.; Cabrera, A.; Capote, H.; Carrasco, A.; Cevallos Yepez, J.; Chavez, E.; Chertkow, H.; Chyrchel-paszkiewicz, U.; Ciabarra, A.; Clemmons, E.; Cohen, D.; Cohen, R.; Cohen, I.; Concha, M.; Costell, B.; Crimmins, D.; Cruz-pagan, Y.; Cueli, A.; Cupelo, R.; Czarnecki, M.; Darby, D.; Dautzenberg, P.; De Deyn, P.; De La Gandara, J.; Deck, K.; Dibenedetto, D.; Dibuono, M.; Dinnerstein, E.; Dirican, A.; Dixit, S.; Dobryniewski, J.; Drake, R.; Drysdale, P.; Duara, R.; Duffy, J.; Ellenbogen, A.; Faradji, V.; Feinberg, M.; Feldman, R.; Fishman, S.; Flitman, S.; Forchetti, C.; Fraga, I.; Frank, A.; Frishberg, B.; Fujigasaki, H.; Fukase, H.; Fumero, I.; Furihata, K.; Galloway, C.; Gandhi, R.; George, K.; Germain, M.; Gitelman, D.; Goetsch, N.; Goldfarb, D.; Goldstein, M.; Goldstick, L.; Gonzalez Rojas, Y.; Goodman, I.; Greeley, D.; Griffin, C.; Grigsby, E.; Grosz, D.; Hafner, K.; Hart, D.; Henein, S.; Herskowitz, B.; Higashi, S.; Higashi, Y.; Ho, G.; Hodgson, J.; Hohenberg, M.; Hollenbeck, L.; Holub, R.; Hori, T.; Hort, J.; Ilkowski, J.; Ingram, K.J.; Isaac, M.; Ishikawa, M.; Janu, L.; Johnston, M.; Julio, W.; Justiz, W.; Kaga, T.; Kakigi, T.; Kalafer, M.; Kamijo, M.; Kaplan, J.; Karathanos, M.; Katayama, S.; Kaul, S.; Keegan, A.; Kerwin, D.; Khan, U.; Khan, A.; Kimura, N.; Kirk, G.; Klodowska, G.; Kowa, H.; Kutz, C.; Kwentus, J.; Lai, R.; Lall, A.; Lawrence, M.; Lee, E.; Leon, R.; Linker, G.; Lisewski, P.; Liss, J.; Liu, C.; Losk, S.; Lukaszyk, E.; Lynch, J.; Macfarlane, S.; Macsweeney, J.; Mannering, N.; Markovic, O.; Marks, D.; Masdeu, J.; Matsui, Y.; Matsuishi, K.; Mcallister, P.; Mcconnehey, B.; Mcelveen, A.; Mcgill, L.; Mecca, A.; Mega, M.; Mensah, J.; Mickielewicz, A.; Minaeian, A.; Mocherla, B.; Murphy, C.; Murphy, P.; Nagashima, H.; Nair, A.; Nair, M.; Nardandrea, J.; Nash, M.; Nasreddine, Z.; Nishida, Y.; Norton, J.; Nunez, L.; Ochiai, J.; Ohkubo, T.; Okamura, Y.; Okorie, E.; Olivera, E.; O’mahony, J.; Omidvar, O.; Ortiz-Cruz, D.; Osowa, A.; Papka, M.; Parker, A.; Patel, P.; Patel, A.; Patel, M.; Patry, C.; Peckham, E.; Pfeffer, M.; Pietras, A.; Plopper, M.; Porsteinsson, A.; Poulin Robitaille, R.; Prins, N.; Puente, O.; Ratajczak, M.; Rhee, M.; Ritter, A.; Rodriguez, R.; Rodriguez Ables, L.; Rojas, J.; Ross, J.; Royer, P.; Rubin, J.; Russell, D.; Rutgers, S.M.; Rutrick, S.; Sadowski, M.; Safirstein, B.; Sagisaka, T.; Scharre, D.; Schneider, L.; Schreiber, C.; Schrift, M.; Schulz, P.; Schwartz, H.; Schwartzbard, J.; Scott, J.; Selem, L.; Sethi, P.; Sha, S.; Sharlin, K.; Sharma, S.; Shiovitz, T.; Shiwach, R.; Sladek, M.; Sloan, B.; Smith, A.; Solomon, P.; Sorial, E.; Sosa, E.; Stedman, M.; Steen, S.; Stein, L.; Stolyar, A.; Stoukides, J.; Sudoh, S.; Sutton, J.; Syed, J.; Szigeti, K.; Tachibana, H.; Takahashi, Y.; Tateno, A.; Taylor, J.D.; Taylor, K.; Tcheremissine, O.; Thebaud, A.; Thein, S.; Thurman, L.; Toenjes, S.; Toji, H.; Toma, M.; Tran, D.; Trueba, P.; Tsujimoto, M.; Turner, R.; Uchiyama, A.; Ussorowska, D.; Vaishnavi, S.; Valor, E.; Vandersluis, J.; Vasquez, A.; Velez, J.; Verghese, C.; Vodickova-borzova, K.; Watson, D.; Weidman, D.; Weisman, D.; White, A.; Willingham, K.; Winkel, I.; Winner, P.; Winston, J.; Wolff, A.; Yagi, H.; Yamamoto, H.; Yathiraj, S.; Yoshiyama, Y.; Zboch, M. Donanemab in early symptomatic Alzheimer disease. JAMA, 2023, 330(6), 512-527.
[http://dx.doi.org/10.1001/jama.2023.13239] [PMID: 37459141]
[29]
Klein, E.G.; Schroeder, K.; Wessels, A.M.; Phipps, A.; Japha, M.; Schilling, T.; Zimmer, J.A. How donanemab data address the coverage with evidence development questions. Alzheimers Dement., 2024, 20(4), 3127-3140.
[http://dx.doi.org/10.1002/alz.13700] [PMID: 38323738]
[30]
Siman, R.; Scott, R.W. Strategies to alter the progression of Alzheimer’s disease. Curr. Opin. Biotechnol., 1996, 7(6), 601-607.
[http://dx.doi.org/10.1016/S0958-1669(96)80070-X] [PMID: 8939637]
[31]
Bitencourt, A.L.B.; Campos, R.M.; Cline, E.N.; Klein, W.L.; Sebollela, A. Antibody fragments as tools for elucidating structure-toxicity relationships and for diagnostic/therapeutic targeting of neurotoxic amyloid oligomers. Int. J. Mol. Sci., 2020, 21(23), 8920.
[http://dx.doi.org/10.3390/ijms21238920] [PMID: 33255488]
[32]
Liu, Y.; Cheng, X.; Li, H.; Hui, S.; Zhang, Z.; Xiao, Y.; Peng, W. Non-coding RNAs as novel regulators of neuroinflammation in Alzheimer’s disease. Front. Immunol., 2022, 13, 908076.
[http://dx.doi.org/10.3389/fimmu.2022.908076] [PMID: 35720333]
[33]
Zhang, Y.; Zhao, Y.; Ao, X.; Yu, W.; Zhang, L.; Wang, Y.; Chang, W. The role of non-coding RNAs in Alzheimer’s disease: From regulated mechanism to therapeutic targets and diagnostic biomarkers. Front. Aging Neurosci., 2021, 13, 654978.
[http://dx.doi.org/10.3389/fnagi.2021.654978] [PMID: 34276336]
[34]
Sun, H.; Zhu, X.; Lu, P.Y.; Rosato, R.R.; Tan, W.; Zu, Y. Oligonucleotide aptamers: New tools for targeted cancer therapy. Mol. Ther. Nucleic Acids, 2014, 3(8), e182.
[http://dx.doi.org/10.1038/mtna.2014.32] [PMID: 25093706]
[35]
Ylera, F.; Lurz, R.; Erdmann, V.A.; Fürste, J.P. Selection of RNA aptamers to the Alzheimer’s disease amyloid peptide. Biochem. Biophys. Res. Commun., 2002, 290(5), 1583-1588.
[http://dx.doi.org/10.1006/bbrc.2002.6354] [PMID: 11820803]
[36]
Meng, H.M.; Fu, T.; Zhang, X.B.; Tan, W. Cell-SELEX-based aptamer-conjugated nanomaterials for cancer diagnosis and therapy. Natl. Sci. Rev., 2015, 2(1), 71-84.
[http://dx.doi.org/10.1093/nsr/nwv001]
[37]
Lau, J.L.; Dunn, M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg. Med. Chem., 2018, 26(10), 2700-2707.
[http://dx.doi.org/10.1016/j.bmc.2017.06.052] [PMID: 28720325]
[38]
Aileen, F.S.; Willbold, D. Peptides for therapy and diagnosis of Alzheimer’s disease. Curr. Pharm. Des., 2012, 18(6), 755-767.
[http://dx.doi.org/10.2174/138161212799277752] [PMID: 22236121]
[39]
Min, L.J.; Kobayashi, Y.; Mogi, M.; Tsukuda, K.; Yamada, A.; Yamauchi, K.; Abe, F.; Iwanami, J.; Xiao, J.Z.; Horiuchi, M. Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice. PLoS One, 2017, 12(2), e0171515.
[http://dx.doi.org/10.1371/journal.pone.0171515] [PMID: 28158298]
[40]
Sanchis, I.; Spinelli, R.; Aschemacher, N.; Humpola, M.V.; Siano, A. Acetylcholinesterase inhibitory activity of a naturally occurring peptide isolated from Boana pulchella (Anura: Hylidae) and its analogs. Amino Acids, 2020, 52(3), 387-396.
[http://dx.doi.org/10.1007/s00726-019-02815-1] [PMID: 31902008]
[41]
Spicer, C.D.; Jumeaux, C.; Gupta, B.; Stevens, M.M. Peptide and protein nanoparticle conjugates: Versatile platforms for biomedical applications. Chem. Soc. Rev., 2018, 47(10), 3574-3620.
[http://dx.doi.org/10.1039/C7CS00877E] [PMID: 29479622]
[42]
Neves, A.R.; Queiroz, J.F.; Reis, S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J. Nanobiotechnology, 2016, 14(1), 27.
[http://dx.doi.org/10.1186/s12951-016-0177-x] [PMID: 27061902]
[43]
Luo, M.; Lewik, G.; Ratcliffe, J.C.; Choi, C.H.J.; Mäkilä, E.; Tong, W.Y.; Voelcker, N.H. Systematic evaluation of transferrin-modified porous silicon nanoparticles for targeted delivery of doxorubicin to glioblastoma. ACS Appl. Mater. Interf., 2019, 11(37), 33637-33649.
[http://dx.doi.org/10.1021/acsami.9b10787] [PMID: 31433156]
[44]
Lalani, J.; Raichandani, Y.; Mathur, R.; Lalan, M.; Chutani, K.; Mishra, A.K.; Misra, A. Comparative receptor based brain delivery of tramadol-loaded poly(lactic-co-glycolic acid) nanoparticles. J. Biomed. Nanotechnol., 2012, 8(6), 918-927.
[http://dx.doi.org/10.1166/jbn.2012.1462] [PMID: 23030000]
[45]
Demeule, M.; Poirier, J.; Jodoin, J.; Bertrand, Y.; Desrosiers, R.R.; Dagenais, C.; Nguyen, T.; Lanthier, J.; Gabathuler, R.; Kennard, M.; Jefferies, W.A.; Karkan, D.; Tsai, S.; Fenart, L.; Cecchelli, R.; Béliveau, R. High transcytosis of melanotransferrin (P97) across the blood–brain barrier. J. Neurochem., 2002, 83(4), 924-933.
[http://dx.doi.org/10.1046/j.1471-4159.2002.01201.x] [PMID: 12421365]
[46]
Livnah, O.; Bayer, E.A.; Wilchek, M.; Sussman, J.L. Three-dimensional structures of avidin and the avidin-biotin complex. Proc. Natl. Acad. Sci. USA, 1993, 90(11), 5076-5080.
[http://dx.doi.org/10.1073/pnas.90.11.5076] [PMID: 8506353]
[47]
Lyu, Y.; Martínez, Á.; D’Incà, F.; Mancin, F.; Scrimin, P. The biotin–avidin interaction in biotinylated gold nanoparticles and the modulation of their aggregation. Nanomaterials (Basel), 2021, 11(6), 1559.
[http://dx.doi.org/10.3390/nano11061559] [PMID: 34199307]
[48]
Khan, N.H.; Mir, M.; Ngowi, E.E.; Zafar, U.; Khakwani, M.M.A.K.; Khattak, S.; Zhai, Y.K.; Jiang, E.S.; Zheng, M.; Duan, S.F.; Wei, J.S.; Wu, D.D.; Ji, X.Y. Nanomedicine: A promising way to manage Alzheimer’s disease. Front. Bioeng. Biotechnol., 2021, 9, 630055.
[http://dx.doi.org/10.3389/fbioe.2021.630055] [PMID: 33996777]
[49]
Bondy, S.C.; Kirstein, S. The promotion of iron-induced generation of reactive oxygen species in nerve tissue by aluminum. Mol. Chem. Neuropathol., 1996, 27(2), 185-194.
[http://dx.doi.org/10.1007/BF02815093] [PMID: 8962602]
[50]
Salvador, G.A. Iron in neuronal function and dysfunction. Biofactors, 2010, 36(2), 103-110.
[http://dx.doi.org/10.1002/biof.80] [PMID: 20232345]
[51]
Bonda, D.J.; Lee, H.; Blair, J.A.; Zhu, X.; Perry, G.; Smith, M.A. Role of metal dyshomeostasis in Alzheimer’s disease. Metallomics, 2011, 3(3), 267-270.
[http://dx.doi.org/10.1039/c0mt00074d] [PMID: 21298161]
[52]
Choi, M.; Ryu, J.; Vu, H.D.; Kim, D.; Youn, Y.J.; Park, M.H.; Huynh, P.T.; Hwang, G.B.; Youn, S.W.; Jeong, Y.H. Transferrin-conjugated melittin-loaded l-arginine-coated iron oxide nanoparticles for mitigating beta-amyloid pathology of the 5XFAD mouse brain. Int. J. Mol. Sci., 2023, 24(19), 14954.
[http://dx.doi.org/10.3390/ijms241914954] [PMID: 37834402]
[53]
Piemontese, L.; Vitucci, G.; Catto, M.; Laghezza, A.; Perna, F.M.; Rullo, M.; Loiodice, F.; Capriati, V.; Solfrizzo, M. Natural scaffolds with multi-target activity for the potential treatment of Alzheimer’s disease. Molecules, 2018, 23(9), 2182.
[http://dx.doi.org/10.3390/molecules23092182] [PMID: 30158491]
[54]
Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry, 1999, 66(2), 137-147.
[http://dx.doi.org/10.1136/jnnp.66.2.137] [PMID: 10071091]
[55]
Pilotaz, F.; Masson, P.; Huperzine, A. An acetylcholinesterase inhibitor with high pharmacological potential. Ann. Pharm. Fr., 1999, 57(5), 363-373.
[PMID: 10520506]
[56]
Thakur, G.; Micic, M.; Yang, Y.; Li, W.; Movia, D.; Giordani, S.; Zhang, H.; Leblanc, R.M. Conjugated quantum dots inhibit the amyloid β (1–42) fibrillation process. Int. J. Alzheimers Dis., 2011, 2011(1), 502386.
[http://dx.doi.org/10.4061/2011/502386] [PMID: 21423556]
[57]
Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Gu, G.; Song, Q.; Yao, L.; Hu, Q.; Tu, Y.; Pang, Z.; Chen, H.; Jiang, X.; Gao, X.; Chen, J. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials, 2013, 34(15), 3870-3881.
[http://dx.doi.org/10.1016/j.biomaterials.2013.02.003] [PMID: 23453061]
[58]
Prades, R.; Guerrero, S.; Araya, E.; Molina, C.; Salas, E.; Zurita, E.; Selva, J.; Egea, G.; López-Iglesias, C.; Teixidó, M.; Kogan, M.J.; Giralt, E. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials, 2012, 33(29), 7194-7205.
[http://dx.doi.org/10.1016/j.biomaterials.2012.06.063] [PMID: 22795856]
[59]
Nie, Y.; Schaffert, D.; Rödl, W.; Ogris, M.; Wagner, E.; Günther, M. Dual-targeted polyplexes: One step towards a synthetic virus for cancer gene therapy. J. Control. Release, 2011, 152(1), 127-134.
[http://dx.doi.org/10.1016/j.jconrel.2011.02.028] [PMID: 21392549]
[60]
Staquicini, F.I.; Ozawa, M.G.; Moya, C.A.; Driessen, W.H.P.; Barbu, E.M.; Nishimori, H.; Soghomonyan, S.; Flores, L.G., II; Liang, X.; Paolillo, V.; Alauddin, M.M.; Basilion, J.P.; Furnari, F.B.; Bogler, O.; Lang, F.F.; Aldape, K.D.; Fuller, G.N.; Höök, M.; Gelovani, J.G.; Sidman, R.L.; Cavenee, W.K.; Pasqualini, R.; Arap, W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest., 2011, 121(1), 161-173.
[http://dx.doi.org/10.1172/JCI44798] [PMID: 21183793]
[61]
Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; Chen, H.; Jiang, X.; Chen, J. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug. Chem., 2013, 24(6), 997-1007.
[http://dx.doi.org/10.1021/bc400055h] [PMID: 23718945]
[62]
Wang, B.; Yu, B.; Karim, M.; Hu, H.; Sun, Y.; McGreevy, P.; Petocz, P.; Held, S.; Brand-Miller, J. Dietary sialic acid supplementation improves learning and memory in piglets. Am. J. Clin. Nutr., 2007, 85(2), 561-569.
[http://dx.doi.org/10.1093/ajcn/85.2.561] [PMID: 17284758]
[63]
Yin, T.; Yang, L.; Liu, Y.; Zhou, X.; Sun, J.; Liu, J. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood–brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease. Acta Biomater., 2015, 25, 172-183.
[http://dx.doi.org/10.1016/j.actbio.2015.06.035] [PMID: 26143603]
[64]
Rahman, M. Magnetic resonance imaging and iron-oxide nanoparticles in the era of personalized medicine. Nanotheranostics, 2023, 7(4), 424-449.
[http://dx.doi.org/10.7150/ntno.86467] [PMID: 37650011]
[65]
Rinaudo, M. Main properties and current applications of some polysaccharides as biomaterials. Polym. Int., 2008, 57(3), 397-430.
[http://dx.doi.org/10.1002/pi.2378]
[66]
Kang, M.L.; Cho, C.S.; Yoo, H.S. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol. Adv., 2009, 27(6), 857-865.
[http://dx.doi.org/10.1016/j.biotechadv.2009.06.007] [PMID: 19583998]
[67]
Rhee, I.; Hong, S.; Chang, Y. Chitosan-coated ferrite (Fe3O4) nanoparticles as a T2 contrast agent for magnetic resonance imaging. J. Korean Phys. Soc., 2010, 56(3), 868-873.
[http://dx.doi.org/10.3938/jkps.56.868]
[68]
Yao, X.; Qi, C.; Sun, C.; Huo, F.; Jiang, X. Poly(ethylene glycol) alternatives in biomedical applications. Nano Today, 2023, 48, 101738.
[http://dx.doi.org/10.1016/j.nantod.2022.101738]
[69]
Yu, M.; Huang, S.; Yu, K.J.; Clyne, A.M. Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Int. J. Mol. Sci., 2012, 13(5), 5554-5570.
[http://dx.doi.org/10.3390/ijms13055554] [PMID: 22754315]
[70]
Cole, A.J.; David, A.E.; Wang, J.; Galbán, C.J.; Hill, H.L.; Yang, V.C. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials, 2011, 32(8), 2183-2193.
[http://dx.doi.org/10.1016/j.biomaterials.2010.11.040] [PMID: 21176955]
[71]
Tong, S.; Hou, S.; Zheng, Z.; Zhou, J.; Bao, G. Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett., 2010, 10(11), 4607-4613.
[http://dx.doi.org/10.1021/nl102623x] [PMID: 20939602]
[72]
Mehvar, R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Cont. Rel., 2000, 69(1), 1-25.
[http://dx.doi.org/10.1016/S0168-3659(00)00302-3] [PMID: 11018543]
[73]
Van Tomme, S.R.; Hennink, W.E. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev. Med. Devices, 2007, 4(2), 147-164.
[http://dx.doi.org/10.1586/17434440.4.2.147] [PMID: 17359222]
[74]
Khalikova, E.; Susi, P.; Korpela, T. Microbial dextran-hydrolyzing enzymes: Fundamentals and applications. Microbiol. Mol. Biol. Rev., 2005, 69(2), 306-325.
[http://dx.doi.org/10.1128/MMBR.69.2.306-325.2005] [PMID: 15944458]
[75]
Kouyoumdjian, H.; Zhu, D.C.; El-Dakdouki, M.H.; Lorenz, K.; Chen, J.; Li, W.; Huang, X. Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. ACS Chem. Neurosci., 2013, 4(4), 575-584.
[http://dx.doi.org/10.1021/cn3002015] [PMID: 23590250]
[76]
Martins, C.; Sousa, F.; Araújo, F.; Sarmento, B. Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications. Adv. Healthc. Mater., 2018, 7(1), 1701035.
[http://dx.doi.org/10.1002/adhm.201701035] [PMID: 29171928]
[77]
Toyos-Rodríguez, C.; Llamedo-González, A.; Pando, D.; García, S.; García, J.A.; García-Alonso, F.J.; de la Escosura-Muñiz, A. Novel magnetic beads with improved performance for Alzheimer’s disease biomarker detection. Microchem. J., 2022, 175, 107211.
[http://dx.doi.org/10.1016/j.microc.2022.107211]
[78]
Riccardi, C.; Napolitano, F.; Montesarchio, D.; Sampaolo, S.; Melone, M.A.B. Nanoparticle-guided brain drug delivery: Expanding the therapeutic approach to neurodegenerative diseases. Pharmaceutics, 2021, 13(11), 1897.
[http://dx.doi.org/10.3390/pharmaceutics13111897] [PMID: 34834311]
[79]
Zou, K.; Gong, J.S.; Yanagisawa, K.; Michikawa, M. A novel function of monomeric amyloid β-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci., 2002, 22(12), 4833-4841.
[http://dx.doi.org/10.1523/JNEUROSCI.22-12-04833.2002] [PMID: 12077180]
[80]
Liu, J.L.; Fan, Y.G.; Yang, Z.S.; Wang, Z.Y.; Guo, C. Iron and Alzheimer’s disease: From pathogenesis to therapeutic implications. Front. Neurosci., 2018, 12, 632.
[http://dx.doi.org/10.3389/fnins.2018.00632] [PMID: 30250423]
[81]
Rivas-Arancibia, S.; Rodriguez-Martinez, E.; Méndez-García, A.; Moctezuma-Salgado, M.; Jiménez-Espíndola, P.; López-Gonzales, U. Oxidative stress, inflammation, and formation of Beta‐Amyloid 1‐42 in brain. In: Free Radicals and Diseases; Intechopen: London, UK, 2016, pp. 1-10.
[http://dx.doi.org/10.5772/64709]
[82]
Islam, F.; Shohag, S.; Akhter, S.; Islam, M.R.; Sultana, S.; Mitra, S.; Chandran, D.; Khandaker, M.U.; Ashraf, G.M.; Idris, A.M.; Emran, T.B.; Cavalu, S. Exposure of metal toxicity in Alzheimer’s disease: An extensive review. Front. Pharmacol., 2022, 13, 903099.
[http://dx.doi.org/10.3389/fphar.2022.903099] [PMID: 36105221]
[83]
Sonia, T.A.; Sharma, C.P. Lipids and inorganic nanoparticles in oral insulin delivery. In: Oral Delivery of Insulin; Elsevier: Amsterdam, Netherlands, 2014, pp. 219-256.
[http://dx.doi.org/10.1533/9781908818683.219]
[84]
Ilinskaya, A.N.; Dobrovolskaia, M.A. Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol. Appl. Pharmacol., 2016, 299, 70-77.
[http://dx.doi.org/10.1016/j.taap.2016.01.005] [PMID: 26773813]
[85]
Graván, P.; Peña-Martín, J.; de Andrés, J.L.; Pedrosa, M.; Villegas-Montoya, M.; Galisteo-González, F.; Marchal, J.A.; Sánchez-Moreno, P. Exploring the impact of nanoparticle stealth coatings in cancer models: From pegylation to cell membrane-coating nanotechnology. ACS Appl. Mater. Interfaces, 2024, 16(2), 2058-2074.
[http://dx.doi.org/10.1021/acsami.3c13948] [PMID: 38159050]
[86]
Abbas, M. Potential role of nanoparticles in treating the accumulation of amyloid-beta peptide in Alzheimer’s patients. Polymers (Basel), 2021, 13(7), 1051.
[http://dx.doi.org/10.3390/polym13071051] [PMID: 33801619]
[87]
Chiang, M.C.; Yang, Y.P.; Nicol, C.J.B.; Wang, C.J. Gold nanoparticles in neurological diseases: A review of neuroprotection. Int. J. Mol. Sci., 2024, 25(4), 2360.
[http://dx.doi.org/10.3390/ijms25042360] [PMID: 38397037]
[88]
Ferrag, C.; Kerman, K. Grand challenges in nanomaterial-based electrochemical sensors. Front. Sens., 2020, 1, 583822.
[http://dx.doi.org/10.3389/fsens.2020.583822]
[89]
Thanh, N.T.K.; Green, L.A.W. Functionalisation of nanoparticles for biomedical applications. Nano Today, 2010, 5(3), 213-230.
[http://dx.doi.org/10.1016/j.nantod.2010.05.003]
[90]
Srinoi, P.; Chen, Y.T.; Vittur, V.; Marquez, M.D.; Lee, T.R. Bimetallic nanoparticles: Enhanced magnetic and optical properties for emerging biological applications. Appl. Sci. (Basel), 2018, 8(7), 1106.
[http://dx.doi.org/10.3390/app8071106]
[91]
Micaelo, A.; Rodriguez, E.; Millan, A.; Gongora, R.; Fuentes, M. Protein interactions and nanomaterials: A key role of the protein corona in nanobiocompatibility. In: Protein-Protein Interaction Assays; Intechopen: London, UK, 2018, pp. 1-9.
[http://dx.doi.org/10.5772/intechopen.75501]
[92]
Guerrini, L.; Alvarez-Puebla, R.A.; Pazos-Perez, N. Surface modifications of nanoparticles for stability in biological fluids. Materials (Basel), 2018, 11(7), 1154.
[http://dx.doi.org/10.3390/ma11071154] [PMID: 29986436]
[93]
Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm., 2008, 5(4), 505-515.
[http://dx.doi.org/10.1021/mp800051m] [PMID: 18672949]
[94]
Tian, M.; Dong, B.; Li, W.; Wang, L.; Yu, H. Applications of novel microscale and nanoscale materials for theranostics: From design to clinical translation. Pharmaceutics, 2024, 16(10), 1339.
[http://dx.doi.org/10.3390/pharmaceutics16101339] [PMID: 39458667]
[95]
Hua, S.; de Matos, M.B.C.; Metselaar, J.M.; Storm, G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization. Front. Pharmacol., 2018, 9, 790.
[http://dx.doi.org/10.3389/fphar.2018.00790] [PMID: 30065653]
[96]
Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131(5), 861-872.
[http://dx.doi.org/10.1016/j.cell.2007.11.019] [PMID: 18035408]
[97]
Soza-Ried, J.; Fisher, A.G. Reprogramming somatic cells towards pluripotency by cellular fusion. Curr. Opin. Genet. Dev., 2012, 22(5), 459-465.
[http://dx.doi.org/10.1016/j.gde.2012.07.005] [PMID: 22868176]
[98]
Chen, J.; Zhou, L.; Pan, S. A brief review of recent advances in stem cell biology. Neural Regen. Res., 2014, 9(7), 684-687.
[http://dx.doi.org/10.4103/1673-5374.131565] [PMID: 25206872]
[99]
Zhou, H.; Wu, S.; Joo, J.Y.; Zhu, S.; Han, D.W.; Lin, T.; Trauger, S.; Bien, G.; Yao, S.; Zhu, Y.; Siuzdak, G.; Schöler, H.R.; Duan, L.; Ding, S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 2009, 4(5), 381-384.
[http://dx.doi.org/10.1016/j.stem.2009.04.005] [PMID: 19398399]
[100]
Wernig, M.; Meissner, A.; Foreman, R.; Brambrink, T.; Ku, M.; Hochedlinger, K.; Bernstein, B.E.; Jaenisch, R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature, 2007, 448(7151), 318-324.
[http://dx.doi.org/10.1038/nature05944] [PMID: 17554336]
[101]
Yu, J.; Vodyanik, M.A.; Smuga-Otto, K. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007, 318(5858), 1917-1920.
[http://dx.doi.org/10.1126/science.1151526] [PMID: 18029452]
[102]
Harui, A.; Suzuki, S.; Kochanek, S.; Mitani, K. Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol., 1999, 73(7), 6141-6146.
[http://dx.doi.org/10.1128/JVI.73.7.6141-6146.1999] [PMID: 10364373]
[103]
Okita, K.; Ichisaka, T.; Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature, 2007, 448(7151), 313-317.
[http://dx.doi.org/10.1038/nature05934] [PMID: 17554338]
[104]
Warren, L.; Manos, P.D.; Ahfeldt, T.; Loh, Y.H.; Li, H.; Lau, F.; Ebina, W.; Mandal, P.K.; Smith, Z.D.; Meissner, A.; Daley, G.Q.; Brack, A.S.; Collins, J.J.; Cowan, C.; Schlaeger, T.M.; Rossi, D.J. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 2010, 7(5), 618-630.
[http://dx.doi.org/10.1016/j.stem.2010.08.012] [PMID: 20888316]
[105]
Yusa, K.; Rad, R.; Takeda, J.; Bradley, A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat. Methods, 2009, 6(5), 363-369.
[http://dx.doi.org/10.1038/nmeth.1323] [PMID: 19337237]
[106]
Si, Z.; Wang, X. Stem cell therapies in Alzheimer’s disease: Applications for disease modeling. J. Pharmacol. Exp. Ther., 2021, 377(2), 207-217.
[http://dx.doi.org/10.1124/jpet.120.000324] [PMID: 33558427]
[107]
Heidenreich, M.; Zhang, F. Applications of CRISPR–Cas systems in neuroscience. Nat. Rev. Neurosci., 2016, 17(1), 36-44.
[http://dx.doi.org/10.1038/nrn.2015.2] [PMID: 26656253]
[108]
Penney, J.; Ralvenius, W.T.; Tsai, L.H. Modeling Alzheimer’s disease with iPSC-derived brain cells. Mol. Psychiatry, 2020, 25(1), 148-167.
[http://dx.doi.org/10.1038/s41380-019-0468-3] [PMID: 31391546]
[109]
Oksanen, M.; Petersen, A.J.; Naumenko, N.; Puttonen, K.; Lehtonen, Š.; Gubert Olivé, M.; Shakirzyanova, A.; Leskelä, S.; Sarajärvi, T.; Viitanen, M.; Rinne, J.O.; Hiltunen, M.; Haapasalo, A.; Giniatullin, R.; Tavi, P.; Zhang, S.C.; Kanninen, K.M.; Hämäläinen, R.H.; Koistinaho, J. PSEN1 mutant ipsc-derived model reveals severe astrocyte pathology in Alzheimer’s disease. Stem Cell Reports, 2017, 9(6), 1885-1897.
[http://dx.doi.org/10.1016/j.stemcr.2017.10.016] [PMID: 29153989]
[110]
Kondo, T.; Asai, M.; Tsukita, K.; Kutoku, Y.; Ohsawa, Y.; Sunada, Y.; Imamura, K.; Egawa, N.; Yahata, N.; Okita, K.; Takahashi, K.; Asaka, I.; Aoi, T.; Watanabe, A.; Watanabe, K.; Kadoya, C.; Nakano, R.; Watanabe, D.; Maruyama, K.; Hori, O.; Hibino, S.; Choshi, T.; Nakahata, T.; Hioki, H.; Kaneko, T.; Naitoh, M.; Yoshikawa, K.; Yamawaki, S.; Suzuki, S.; Hata, R.; Ueno, S.; Seki, T.; Kobayashi, K.; Toda, T.; Murakami, K.; Irie, K.; Klein, W.L.; Mori, H.; Asada, T.; Takahashi, R.; Iwata, N.; Yamanaka, S.; Inoue, H. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell, 2013, 12(4), 487-496.
[http://dx.doi.org/10.1016/j.stem.2013.01.009] [PMID: 23434393]
[111]
Chang, C.Y.; Ting, H.C.; Liu, C.A.; Su, H.L.; Chiou, T.W.; Lin, S.Z.; Harn, H.J.; Ho, T.J. Induced pluripotent stem cell (ipsc)-based neurodegenerative disease models for phenotype recapitulation and drug screening. Molecules, 2020, 25(8), 2000.
[http://dx.doi.org/10.3390/molecules25082000] [PMID: 32344649]
[112]
Gaj, T.; Epstein, B.E.; Schaffer, D.V. Genome engineering using adeno-associated virus: Basic and clinical research applications. Mol. Ther., 2016, 24(3), 458-464.
[http://dx.doi.org/10.1038/mt.2015.151] [PMID: 26373345]
[113]
Ishino, Y.; Shinagawa, H.; Makino, K.; Amemura, M.; Nakata, A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol., 1987, 169(12), 5429-5433.
[http://dx.doi.org/10.1128/jb.169.12.5429-5433.1987] [PMID: 3316184]
[114]
Mir, A.; Edraki, A.; Lee, J.; Sontheimer, E.J. Type II-C CRISPR-Cas9 biology, mechanism, and application. ACS Chem. Biol., 2018, 13(2), 357-365.
[http://dx.doi.org/10.1021/acschembio.7b00855] [PMID: 29202216]
[115]
Liao, H.; Wu, J.; VanDusen, N.J.; Li, Y.; Zheng, Y. CRISPR-Cas9-mediated homology-directed repair for precise gene editing. Mol. Ther. Nucleic Acids, 2024, 35(4), 102344.
[http://dx.doi.org/10.1016/j.omtn.2024.102344] [PMID: 39494147]
[116]
Park, H.; Oh, J.; Shim, G.; Cho, B.; Chang, Y.; Kim, S.; Baek, S.; Kim, H.; Shin, J.; Choi, H.; Yoo, J.; Kim, J.; Jun, W.; Lee, M.; Lengner, C.J.; Oh, Y.K.; Kim, J. In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease. Nat. Neurosci., 2019, 22(4), 524-528.
[http://dx.doi.org/10.1038/s41593-019-0352-0] [PMID: 30858603]
[117]
Dissen, G.A.; McBride, J.; Lomniczi, A. Using lentiviral vectors as delivery vehicles for gene therapy.In: Controlled Genetic Manipulations. Neuromethods; Humana Press: Totowa, NJ; , 2012, 65, pp. 69-96.
[http://dx.doi.org/10.1007/978-1-61779-533-6_4]
[118]
Anzalone, A.V.; Randolph, P.B.; Davis, J.R.; Sousa, A.A.; Koblan, L.W.; Levy, J.M.; Chen, P.J.; Wilson, C.; Newby, G.A.; Raguram, A.; Liu, D.R. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 2019, 576(7785), 149-157.
[http://dx.doi.org/10.1038/s41586-019-1711-4] [PMID: 31634902]
[119]
Yang, J.; Li, Y.; Aguilar, A.; Liu, Z.; Yang, C.Y.; Wang, S. Simple structural modifications converting a bona fide MDM2 protac degrader into a molecular glue molecule: A cautionary tale in the design of protac degraders. J. Med. Chem., 2019, 62(21), 9471-9487.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00846] [PMID: 31560543]
[120]
Inuzuka, H.; Liu, J.; Wei, W.; Rezaeian, A.H. PROTAC technology for the treatment of Alzheimer’s disease: Advances and perspectives. Acta Materia Med., 2022, 1(1), 24-41.
[http://dx.doi.org/10.15212/AMM-2021-0001] [PMID: 35237768]
[121]
Farnaby, W.; Koegl, M.; Roy, M.J.; Whitworth, C.; Diers, E.; Trainor, N.; Zollman, D.; Steurer, S.; Karolyi-Oezguer, J.; Riedmueller, C.; Gmaschitz, T.; Wachter, J.; Dank, C.; Galant, M.; Sharps, B.; Rumpel, K.; Traxler, E.; Gerstberger, T.; Schnitzer, R.; Petermann, O.; Greb, P.; Weinstabl, H.; Bader, G.; Zoephel, A.; Weiss-Puxbaum, A.; Ehrenhöfer-Wölfer, K.; Wöhrle, S.; Boehmelt, G.; Rinnenthal, J.; Arnhof, H.; Wiechens, N.; Wu, M.Y.; Owen-Hughes, T.; Ettmayer, P.; Pearson, M.; McConnell, D.B.; Ciulli, A. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol., 2019, 15(7), 672-680.
[http://dx.doi.org/10.1038/s41589-019-0294-6] [PMID: 31178587]
[122]
Smith, B.E.; Wang, S.L.; Jaime-Figueroa, S.; Harbin, A.; Wang, J.; Hamman, B.D.; Crews, C.M. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun., 2019, 10(1), 131.
[http://dx.doi.org/10.1038/s41467-018-08027-7] [PMID: 30631068]
[123]
Chu, T.T.; Gao, N.; Li, Q.Q.; Chen, P.G.; Yang, X.F.; Chen, Y.X.; Zhao, Y.F.; Li, Y.M. Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation. Cell Chem. Biol., 2016, 23(4), 453-461.
[http://dx.doi.org/10.1016/j.chembiol.2016.02.016] [PMID: 27105281]
[124]
Wang, W.; Zhou, Q.; Jiang, T.; Li, S.; Ye, J.; Zheng, J.; Wang, X.; Liu, Y.; Deng, M.; Ke, D.; Wang, Q.; Wang, Y.; Wang, J.Z. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics, 2021, 11(11), 5279-5295.
[http://dx.doi.org/10.7150/thno.55680] [PMID: 33859747]
[125]
Swanson, C.J.; Zhang, Y.; Dhadda, S.; Wang, J.; Kaplow, J.; Lai, R.Y.K.; Lannfelt, L.; Bradley, H.; Rabe, M.; Koyama, A.; Reyderman, L.; Berry, D.A.; Berry, S.; Gordon, R.; Kramer, L.D.; Cummings, J.L. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res. Ther., 2021, 13(1), 80.
[http://dx.doi.org/10.1186/s13195-021-00813-8] [PMID: 33865446]
[126]
Dornieden, S.; Müller-Schiffmann, A.; Sticht, H. Characterization of a single-chain variable fragment recognizing a linear epitope of aβ: A biotechnical tool for studies on Alzheimer’s disease. PLoS One, 2013, 8(3), e59820.
[http://dx.doi.org/10.1371/journal.pone.0059820] [PMID: 23555792]
[127]
Zhang, Y.; Huai, Y.; Zhang, X.; Song, C.; Cai, J.; Zhang, Y. The mode of action of an anti-oligomeric amyloid β-protein antibody affects its protective efficacy. Neurotox. Res., 2019, 35(2), 304-317.
[http://dx.doi.org/10.1007/s12640-018-9955-6] [PMID: 30229545]
[128]
Tamura, Y.; Hamajima, K.; Matsui, K.; Yanoma, S.; Narita, M.; Tajima, N.; Xin, K.Q.; Klinman, D.; Okuda, K. The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain. Neurobiol. Dis., 2005, 20(2), 541-549.
[http://dx.doi.org/10.1016/j.nbd.2005.04.007] [PMID: 15908227]
[129]
Antonios, G.; Borgers, H.; Richard, B.C.; Brauß, A.; Meißner, J.; Weggen, S.; Pena, V.; Pillot, T.; Davies, S.L.; Bakrania, P.; Matthews, D.; Brownlees, J.; Bouter, Y.; Bayer, T.A. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Sci. Rep., 2015, 5(1), 17338.
[http://dx.doi.org/10.1038/srep17338] [PMID: 26626428]
[130]
Hu, M.; Zhang, J.; Yang, J.; Cao, Y.; Qi, J. A novel scfv anti-aβ antibody reduces pathological impairments in APP/PS1 transgenic mice via modulation of inflammatory cytokines and AB-related enzymes. J. Mol. Neurosci., 2018, 66(1), 1-9.
[http://dx.doi.org/10.1007/s12031-018-1139-6] [PMID: 30062438]
[131]
Liu, R.; Yuan, B.; Emadi, S.; Zameer, A.; Schulz, P.; McAllister, C.; Lyubchenko, Y.; Goud, G.; Sierks, M.R. Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. Biochemistry, 2004, 43(22), 6959-6967.
[http://dx.doi.org/10.1021/bi049933o] [PMID: 15170333]
[132]
Nisbet, R.M.; Nigro, J.; Breheney, K.; Caine, J.; Hattarki, M.K.; Nuttall, S.D. Central amyloid-β-specific single chain variable fragment ameliorates Aβ aggregation and neurotoxicity. Protein Eng. Des. Sel., 2013, 26(10), 571-580.
[http://dx.doi.org/10.1093/protein/gzt025] [PMID: 23766374]
[133]
Lafaye, P.; Achour, I.; England, P.; Duyckaerts, C.; Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation. Mol. Immunol., 2009, 46(4), 695-704.
[http://dx.doi.org/10.1016/j.molimm.2008.09.008] [PMID: 18930548]
[134]
Martin-Peña, A.; Rincon-Limas, D.E.; Fernandez-Funez, P. Anti-Aβ single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer’s disease. Sci. Rep., 2017, 7(1), 11268.
[http://dx.doi.org/10.1038/s41598-017-11594-2] [PMID: 28900185]
[135]
Ahmed, B.S.; Baijal, G.; Somashekar, R.; Iyer, S.; Nayak, V. Comparative study of one pot synthesis of PEGylated gold and silver nanoparticles for imaging and radiosensitization of oral cancers. Radiat. Phys. Chem., 2022, 194, 109990.
[http://dx.doi.org/10.1016/j.radphyschem.2022.109990]
[136]
Cui, N.; Lu, H.; Li, M. Magnetic nanoparticles associated peg/plga block copolymer targeted with anti-transferrin receptor antibodies for Alzheimer’s disease. J. Biomed. Nanotechnol., 2018, 14(5), 1017-1024.
[http://dx.doi.org/10.1166/jbn.2018.2512] [PMID: 29883571]
[137]
Yang, L.; Sun, J.; Xie, W.; Liu, Y.; Liu, J. Dual-functional selenium nanoparticles bind to and inhibit amyloid β fiber formation in Alzheimer’s disease. J. Mater. Chem. B Mater. Biol. Med., 2017, 5(30), 5954-5967.
[http://dx.doi.org/10.1039/C6TB02952C] [PMID: 32264352]
[138]
George, D.; Maheswari, P.U.; Begum, K.M.M.S. Chitosan-cellulose hydrogel conjugated with L-histidine and zinc oxide nanoparticles for sustained drug delivery: Kinetics and in-vitro biological studies. Carbohydr. Polym., 2020, 236, 116101.
[http://dx.doi.org/10.1016/j.carbpol.2020.116101] [PMID: 32172900]
[139]
Zhao, F.; Yang, H.; Gao, Z.; Liu, H.; Wu, P.; Li, B.; Yu, H.; Shao, J. Novel fabrication of Cu(II)-incorporated chiral d-penicillamine-chitosan nanocomposites enantio-selectively inhibit the induced amyloid β aggregation for Alzheimer’s disease therapy. Heliyon, 2024, 10(1), e23563.
[http://dx.doi.org/10.1016/j.heliyon.2023.e23563] [PMID: 38223723]

Rights & Permissions Print Cite
© 2026 Bentham Science Publishers | Privacy Policy